Next week Chicago will host the ASN Kidney Week Congress. In preparation for this year’s meeting, the COMPACT RENAL team has summarised key sessions and posters relating to iron deficiency and anaemia.
Note that hyperlinks to symposia will take you to the ASN Kidney Week website, where you will have the option to add sessions to your calendar. Links in  point to abstracts.
Thursday 17 November
Nephrologists interested in iron deficiency and anaemia will find the poster session on Thursday to be of greatest interest during the day.
Posters of interest on Thursday include:
- A post-hoc analysis of the FIND-CKD study, presented by Iain MacDougall, showed a low rate of early responders in patients with NDD-CKD [TH-PO906]
- Results from the C.E. DOSE trial evaluating the impact of high or low dose ESA on a composite of death or a CV event [TH-PO909]
- Four posters analysing the results of a Phase III study of ferric citrate in NDD-CKD patients [TH-PO901, TH-PO902, TH-PO903, TH-PO904]
- New clinical data on HIF-PH inhibitors vadadustat and daprodustat [TH-PO907, TH-PO960, TH-PO908]
Friday 18 November
At 12:45pm, during the first of two HIF-related industry symposium at ASN 2016, current unmet needs in the treatment of anaemia will be discussed, as well as information on HIF biology, development and early clinical experience. Presenters include Mark Koury and Jay Wish, a member of the COMPACT RENAL faculty.
At 2pm, during the clinical science session Marching Forward with New Treatments for Old Ailments, Jeffrey Berns will also discuss the potential role of HIF-PH inhibitors in treating renal anaemia.
Relevant iron deficiency and anaemia posters include:
- Analysis of the prevalence of anaemia in 150,000 Medicare NDD-CKD patients [FR-PO766]
- Assessment of changes in ESA use in NDD-CKD patients over time, and the proportion left untreated [FR-PO767]
Saturday 19 November
At 12:45pm, in the second HIF-related industry symposium, there will be a review of the benefits and risks of current anaemia management, the role of hypoxia in anaemia, and benefits / risks of HIF stabilizers. At the same time, another industry symposium will review new developments in the regulation of iron handling and summarize how these findings may impact the diagnosis and management of iron deficiency in NDD-CKD. Presenters include Steven Fishbane and Tomas Ganz
At 4:30pm, an oral abstract session entitled Opportunities to Improve Dialysis Outcomes: Anaemia and Beyond, will include:
- A DOPPS analysis assessing regional differences in anaemia management during the first 5 years after dialysis initiation [SA-OR110]
- Results from a systemic review and meta-analysis assessing the safety of IV iron in dialysis patients [SA-OR112]
- Findings from the Phase II trial program of daprodustat [SA-OR114]
Posters on Saturday include:
- Data from the FACT-Study comparing ferumoxytol and iron sucrose [SA-PO1009]
- Data from a US Phase III study assessing clinical equivalence of biosimilar epoetin to its US originator product in dialysis patients [SA-PO1006]
Sunday 20 November
There are no iron deficiency or anaemia sessions scheduled for Sunday.
We wish you all a safe trip to Chicago and we look forward to reporting back on the key presentations from the congress.